Deprescribing Cascades and Pharmacist Intervention: A Contemporary Review for Healthcare Professionals

Abstract

Deprescribing cascades occur when adverse effects of medications are misinterpreted as new medical conditions, leading to the prescription of additional drugs and compounding patient risk. Pharmacists, as medication experts, play a pivotal role in identifying and interrupting these cascades, thereby improving patient safety and reducing polypharmacy. This review synthesizes current evidence on deprescribing cascades, elucidates their clinical implications, explores mechanisms and risk factors, and discusses the critical role of pharmacist intervention. The article highlights recent advances, guideline recommendations, and practical strategies for integrating deprescribing into patient care, providing a comprehensive resource for clinicians aiming to optimize pharmacotherapy and mitigate medication-related harm.

Introduction

Polypharmacy, especially among older adults and those with multiple comorbidities, remains a significant challenge in contemporary medicine. Deprescribing cascades, a subset of medication errors, arise when side effects from one medication are misdiagnosed as a new condition, prompting the initiation of further pharmacotherapy. This phenomenon not only exacerbates the risk of adverse drug events (ADEs) but also complicates the clinical trajectory of vulnerable populations. The role of pharmacists in recognizing and mitigating these cascades has garnered increasing attention as a cornerstone of safe prescribing practices in both acute and chronic care settings.

Epidemiology / Disease Burden

The prevalence of polypharmacy, defined as the concurrent use of five or more medications, is increasing globally, with estimates suggesting that up to 40% of adults aged 65 and older are affected. Studies indicate that nearly 10-25% of adverse drug reactions in this population can be attributed to prescribing cascades. The resultant morbidity, hospitalizations, and healthcare costs underscore the clinical and economic burden of these iatrogenic events. Notably, the widespread use of medications such as anticholinergics, antihypertensives, and antipsychotics has been directly implicated in the initiation of prescribing cascades, further emphasizing the need for vigilant medication review.

Pathophysiology

A prescribing cascade typically initiates when a medication produces an adverse effect that mimics a new disease. For example, the use of a calcium channel blocker may lead to lower-extremity edema, which is then treated with a diuretic, inadvertently increasing the risk for electrolyte disturbances or renal impairment. The underlying pathophysiology involves pharmacodynamic and pharmacokinetic interactions, age-related changes in drug metabolism, and an impaired ability of patients particularly the elderly to recover from iatrogenic insults. The cascade perpetuates as new symptoms emerge, creating a feedback loop of additional prescriptions and adverse drug events.

Risk Factors

Risk factors for deprescribing cascades are multifactorial and include advanced age, multimorbidity, cognitive impairment, and transitions of care. Patients with fragmented care and those lacking a consistent primary care provider are at heightened risk. Polypharmacy itself serves as both a cause and consequence of prescribing cascades, and the use of high-risk medications (e.g., anticholinergics, sedatives, NSAIDs) further increases vulnerability. Social determinants, limited health literacy, and inadequate communication among healthcare professionals exacerbate these risks, highlighting the necessity for coordinated, multidisciplinary intervention.

Clinical Features

Clinically, deprescribing cascades may present as a constellation of nonspecific symptoms e.g., fatigue, confusion, falls, or gastrointestinal disturbances that are often attributed to new or worsening medical conditions. The temporal relationship between medication changes and symptom onset is a critical clue. In many cases, the original adverse effect goes unrecognized, and subsequent medications may partially relieve symptoms while introducing new adverse effects. This diagnostic complexity underscores the importance of comprehensive medication reconciliation and a high index of suspicion for drug-induced pathologies.

Diagnosis

Diagnosis requires a systematic approach, beginning with a thorough medication history and review of recent drug changes. Temporal correlation between drug initiation and symptom emergence is essential. Tools such as the Medication Appropriateness Index (MAI) and Beers Criteria can assist clinicians in identifying potentially inappropriate medications. Pharmacists are uniquely positioned to recognize patterns of prescribing cascades through regular medication reviews, chart audits, and patient interviews. Collaboration with prescribers and patients is vital to confirm suspicions and implement deprescribing plans.

Treatment & Management

Effective management centers on the principle of deprescribing systematic withdrawal or dose reduction of medications that are no longer beneficial or are causing harm. The process involves shared decision-making, risk-benefit assessment, and close monitoring for withdrawal effects or symptom recurrence. Pharmacist-led interventions, such as comprehensive medication review, patient education, and provider collaboration, have demonstrated efficacy in reducing inappropriate polypharmacy and improving clinical outcomes. Empowering patients to report new symptoms and engage in discussions about medication necessity further enhances deprescribing efforts.

Recent Advances / Emerging Therapies

Recent advances include the development of electronic health record (EHR)-integrated clinical decision support systems (CDSS) designed to flag potential prescribing cascades and prompt deprescribing considerations. Implementation of validated deprescribing protocols, such as those for proton pump inhibitors or benzodiazepines, has yielded significant reductions in polypharmacy and adverse events. Emerging research supports the integration of pharmacist-led deprescribing clinics and telehealth services, which have shown promise in both community and institutional settings. Educational initiatives aimed at prescribers, pharmacists, and patients are also gaining traction as critical components of cascade prevention.

Guideline Recommendations

Guidelines from organizations such as the American Geriatrics Society and Choosing Wisely advocate for routine medication review and deprescribing in older adults, particularly those with limited life expectancy or high medication burden. Recommendations emphasize the necessity of individualized care, close monitoring, and interprofessional collaboration, with pharmacists playing a central role in the process. Guidelines also stress the importance of avoiding the initiation of additional medications to treat side effects without first considering the role of existing drug therapy.

Conclusion

Deprescribing cascades represent a significant yet often underrecognized contributor to polypharmacy and adverse drug events in clinical practice. Pharmacist intervention is integral to identifying, interrupting, and preventing these cascades through structured medication review, interprofessional communication, and patient engagement. Recent advances in digital health, emerging protocols, and evolving guidelines provide a robust framework for optimizing medication safety. Ongoing education, system-level support, and research into effective deprescribing strategies remain essential to reducing the burden of prescribing cascades and improving outcomes for at-risk populations.